Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
Cited by 11
Related Papers
TMEM147 promotes hepatocellular carcinoma progress by inducing EGFR/MAPK activity
|Research Square (Research Square)|2020|0